Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma

This study is a prospective, open-labelled, monocentric trial. The aim is to observe, in patient with choroidal melanoma (any stage of the disease), the prevalence of the circulating tumor DNA at the diagnostic and its evolution during 3 years.

The patient will have a blood sample at the following times :

• T0: before treatment of the primary tumor.
• T1: 1 months after the end of the local treatment.
• T2: at 7 months.
• Tn: every 6 months up to 3 years.

Inclusion Criteria:

• Aged 18 years old or more.
• Patient with a recent choroidal melanoma before the start of the specific treatment.
• Patient able to stand a blood collection.
• Work-up for extension (CT).
• Patient explanation given and consent information signed or by legal representative

Exclusion Criteria:

• Patient without social protection / insurance.
• Person deprived of liberty or under guardianship.
• Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).